Watchlist Price Alert

Eli Lilly and (LLY)

NYSE: LLY · Real-Time Price · USD

819.67

7.64 (0.94%)

At close: Jun 13, 2025, 3:59 PM

819.81

0.02%

After-hours: Jun 13, 2025, 05:59 PM EDT

0.94% (1D)

Bid	819.02
Market Cap	776.83B
Revenue (ttm)	49B
Net Income (ttm)	11.11B
EPS (ttm)	12.3
PE Ratio (ttm)	66.64
Forward PE	27.25
Analyst	Buy

Ask	819.78
Volume	2,252,517
Avg. Volume (20D)	4,082,458
Open	810.34
Previous Close	812.03
Day's Range	808.10 - 825.00
52-Week Range	677.09 - 972.53
Beta	0.39

About LLY

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol LLY

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for LLY stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

1 month ago

-4.09%

Shares of pharmaceutical stocks are trading lower.... Unlock content with Pro Subscription

1 month ago

-1.26%

Shares of pharmaceutical stocks are trading lower amid President Trump's drug pricing executive order.

News

16 hours ago · barrons.com

Novo Nordisk Is Europe's Most Valuable Company—Again. Eli Lilly, Watch Out.

The Danish drug maker is being more forceful since its CEO departed last month.

17 hours ago · zacks.com

Lilly Moves Past 50-Day Average: Should You Buy the Stock Now?

Eli Lilly and Company LLY has reached a significant support level, making it an attractive option for investors from a technical standpoint. Earlier this week, the stock broke through its 50-day simpl...

18 hours ago · benzinga.com

Zepbound Put Eli Lilly On Top — Now Its Next Big Move Could Supercharge The Stock

Eli Lilly & Co. LLY may be down over 8% in the past month and nearly 5% over the past five days, but JPMorgan analyst Chris Schott isn't backing off. In fact, he's doubling down.

1 day ago · fool.com

Down 12%, Should You Buy the Dip on Eli Lilly?

Eli Lilly (LLY 0.36%) has been a great growth pick for investors over the past few years. The pharma company, thanks to its weight loss drug portfolio, has seen revenue climb in the double digits -- a...

1 day ago · 247wallst.com

Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2025-2030 (June 2025)

From late 2020 to the summer of 2024, Eli Lilly & Co. (NYSE: LLY) stock was on a tear, up more than 635%.

3 days ago · cnbc.com

Healthy Returns: Ozempic, Wegovy linked to rare cases of serious eye condition

Novo Nordisk's drugs are being linked to an eye condition that can cause vision loss, while health tech companies made CNBC's Disruptor 50 List.

2 days ago · zacks.com

Can Mounjaro, Zepbound Help Lilly Maintain Dominance in Obesity Space?

LLY banks on soaring Mounjaro and Zepbound sales to defend its obesity edge amid intensifying competition.

3 days ago · fool.com

Should You Buy Eli Lilly Stock Before June 22?

Eli Lilly (LLY 4.33%) stock hasn't been doing too well this year, but that could change later this month. A couple of key events are on the horizon this month during which the company will release new...

4 days ago · reuters.com

Drug pricing reform talks with US government lack clarity, industry executives say

Talks with the Trump administration about lowering U.S. drug prices have so far not provided clarity on when and how reduced prices will be implemented, top executives from Eli Lilly and Merck said at...

3 days ago · seekingalpha.com

Eli Lilly and Company (LLY) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

Eli Lilly and Company (NYSE:LLY ) Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 8:00 AM ET Company Participants Lucas E. Montarce - Executive VP & CFO Michael Czapar - Director ...

Load More News